Synergistic drug combinations against the in vitro replication of Coxsackie B1 virus
The existence of synergistic drug combinations against the in vitro replication of poliovirus type 1 (Mahoney) (PV-1) had been established in our previous work. The objective of the present study was to test the combined effects of the different drugs against another representative of the enteroviru...
Gespeichert in:
| Veröffentlicht in: | Antiviral research 2004-04, Vol.62 (1), p.9-19 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 19 |
|---|---|
| container_issue | 1 |
| container_start_page | 9 |
| container_title | Antiviral research |
| container_volume | 62 |
| creator | Nikolaeva-Glomb, Lubomira Galabov, Angel S |
| description | The existence of synergistic drug combinations against the in vitro replication of poliovirus type 1 (Mahoney) (PV-1) had been established in our previous work. The objective of the present study was to test the combined effects of the different drugs against another representative of the
enterovirus genus, i.e. Coxsackievirus B1 (CBV-1). Dual combinations of enviroxime, disoxaril, arildone, PTU-23, HBB and S-7 were evaluated.
The susceptibility of CBV-1 to the individual effects of the inhibitors was compared to that of PV-1. CBV-1 was more sensitive to enviroxime, S-7, PTU-23 and HBB and less sensitive to the effects of disoxaril and arildone. The effect of most dual drug combinations tested against CBV-1 replication was additive or synergistic. Enviroxime and S-7, enviroxime and PTU-23, disoxaril and HBB, disoxaril and PTU-23, arildone and HBB, arildone and PTU-23, S-7 and HBB revealed a strong synergistic effect. Synergy against CBV-1 replication was stronger as compared to that noted for the same drug combinations against PV-1 replication. |
| doi_str_mv | 10.1016/j.antiviral.2003.11.001 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_pasteur_00755462v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0166354203002602</els_id><sourcerecordid>17990905</sourcerecordid><originalsourceid>FETCH-LOGICAL-c466t-45fa3147dad65fc2abdf836406da7782dc99f16ed8f19f6b8b4a15346d4db04a3</originalsourceid><addsrcrecordid>eNqF0U2P0zAQBmALgdjuwl8AX-CWMpM4TnIsFbBIlTiwnK2JP7ouaVxsp2L_PSmtdrlx8uXxvKN5GXuLsERA-WG3pDH7o480LEuAaom4BMBnbIFtUxYddPI5W8xSFlUtyit2ndIOAGTTtS_ZFdZQSuyaBbv7_jDauPUpe81NnLZch33vR8o-jInTlvyYMs_3lvuRH32OgUd7GLz-K3hwfB1-J9I_veUfcRZxSq_YC0dDsq8v7w378fnT3fq22Hz78nW92hRaSJkLUTuqUDSGjKydLqk3rq2kAGmoadrS6K5zKK1pHXZO9m0vCOtKSCNMD4KqG1ac597ToA7R7yk-qEBe3a426kAp2ykqgKauhSyPOPv3Z3-I4ddkU1Z7n7QdBhptmJLCppsvB_UMmzPUMaQUrXucjqBOBaideixAnQpQiHPSKeLNJWLq99Y8_btcfAbvLoCSpsFFGrVP_7i6BVHB7FZnZ-cDHr2NKmlvR22Nj1ZnZYL_7zJ_AJ7SqPc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17990905</pqid></control><display><type>article</type><title>Synergistic drug combinations against the in vitro replication of Coxsackie B1 virus</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Nikolaeva-Glomb, Lubomira ; Galabov, Angel S</creator><creatorcontrib>Nikolaeva-Glomb, Lubomira ; Galabov, Angel S</creatorcontrib><description>The existence of synergistic drug combinations against the in vitro replication of poliovirus type 1 (Mahoney) (PV-1) had been established in our previous work. The objective of the present study was to test the combined effects of the different drugs against another representative of the
enterovirus genus, i.e. Coxsackievirus B1 (CBV-1). Dual combinations of enviroxime, disoxaril, arildone, PTU-23, HBB and S-7 were evaluated.
The susceptibility of CBV-1 to the individual effects of the inhibitors was compared to that of PV-1. CBV-1 was more sensitive to enviroxime, S-7, PTU-23 and HBB and less sensitive to the effects of disoxaril and arildone. The effect of most dual drug combinations tested against CBV-1 replication was additive or synergistic. Enviroxime and S-7, enviroxime and PTU-23, disoxaril and HBB, disoxaril and PTU-23, arildone and HBB, arildone and PTU-23, S-7 and HBB revealed a strong synergistic effect. Synergy against CBV-1 replication was stronger as compared to that noted for the same drug combinations against PV-1 replication.</description><identifier>ISSN: 0166-3542</identifier><identifier>EISSN: 1872-9096</identifier><identifier>DOI: 10.1016/j.antiviral.2003.11.001</identifier><identifier>PMID: 15026197</identifier><identifier>CODEN: ARSRDR</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral Agents ; Antiviral Agents - pharmacology ; Benzimidazoles ; Benzimidazoles - pharmacology ; Biological and medical sciences ; Cell Line ; Coxsackievirus B1 ; Drug Combinations ; Drug Synergism ; Enterovirus ; Enterovirus B, Human ; Enterovirus B, Human - drug effects ; Enterovirus B, Human - growth & development ; Humans ; Isoxazoles ; Isoxazoles - pharmacology ; Ketones ; Ketones - pharmacology ; Life Sciences ; Medical sciences ; Microbiology and Parasitology ; Pharmacology. Drug treatments ; Phenylthiourea ; Phenylthiourea - analogs & derivatives ; Phenylthiourea - pharmacology ; Poliovirus ; Pyrimidines ; Pyrimidines - pharmacology ; Synergy ; Virus Replication ; Virus Replication - drug effects</subject><ispartof>Antiviral research, 2004-04, Vol.62 (1), p.9-19</ispartof><rights>2003 Elsevier B.V.</rights><rights>2005 INIST-CNRS</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c466t-45fa3147dad65fc2abdf836406da7782dc99f16ed8f19f6b8b4a15346d4db04a3</citedby><cites>FETCH-LOGICAL-c466t-45fa3147dad65fc2abdf836406da7782dc99f16ed8f19f6b8b4a15346d4db04a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.antiviral.2003.11.001$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,777,781,882,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15580430$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15026197$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://riip.hal.science/pasteur-00755462$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Nikolaeva-Glomb, Lubomira</creatorcontrib><creatorcontrib>Galabov, Angel S</creatorcontrib><title>Synergistic drug combinations against the in vitro replication of Coxsackie B1 virus</title><title>Antiviral research</title><addtitle>Antiviral Res</addtitle><description>The existence of synergistic drug combinations against the in vitro replication of poliovirus type 1 (Mahoney) (PV-1) had been established in our previous work. The objective of the present study was to test the combined effects of the different drugs against another representative of the
enterovirus genus, i.e. Coxsackievirus B1 (CBV-1). Dual combinations of enviroxime, disoxaril, arildone, PTU-23, HBB and S-7 were evaluated.
The susceptibility of CBV-1 to the individual effects of the inhibitors was compared to that of PV-1. CBV-1 was more sensitive to enviroxime, S-7, PTU-23 and HBB and less sensitive to the effects of disoxaril and arildone. The effect of most dual drug combinations tested against CBV-1 replication was additive or synergistic. Enviroxime and S-7, enviroxime and PTU-23, disoxaril and HBB, disoxaril and PTU-23, arildone and HBB, arildone and PTU-23, S-7 and HBB revealed a strong synergistic effect. Synergy against CBV-1 replication was stronger as compared to that noted for the same drug combinations against PV-1 replication.</description><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral Agents</subject><subject>Antiviral Agents - pharmacology</subject><subject>Benzimidazoles</subject><subject>Benzimidazoles - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Cell Line</subject><subject>Coxsackievirus B1</subject><subject>Drug Combinations</subject><subject>Drug Synergism</subject><subject>Enterovirus</subject><subject>Enterovirus B, Human</subject><subject>Enterovirus B, Human - drug effects</subject><subject>Enterovirus B, Human - growth & development</subject><subject>Humans</subject><subject>Isoxazoles</subject><subject>Isoxazoles - pharmacology</subject><subject>Ketones</subject><subject>Ketones - pharmacology</subject><subject>Life Sciences</subject><subject>Medical sciences</subject><subject>Microbiology and Parasitology</subject><subject>Pharmacology. Drug treatments</subject><subject>Phenylthiourea</subject><subject>Phenylthiourea - analogs & derivatives</subject><subject>Phenylthiourea - pharmacology</subject><subject>Poliovirus</subject><subject>Pyrimidines</subject><subject>Pyrimidines - pharmacology</subject><subject>Synergy</subject><subject>Virus Replication</subject><subject>Virus Replication - drug effects</subject><issn>0166-3542</issn><issn>1872-9096</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0U2P0zAQBmALgdjuwl8AX-CWMpM4TnIsFbBIlTiwnK2JP7ouaVxsp2L_PSmtdrlx8uXxvKN5GXuLsERA-WG3pDH7o480LEuAaom4BMBnbIFtUxYddPI5W8xSFlUtyit2ndIOAGTTtS_ZFdZQSuyaBbv7_jDauPUpe81NnLZch33vR8o-jInTlvyYMs_3lvuRH32OgUd7GLz-K3hwfB1-J9I_veUfcRZxSq_YC0dDsq8v7w378fnT3fq22Hz78nW92hRaSJkLUTuqUDSGjKydLqk3rq2kAGmoadrS6K5zKK1pHXZO9m0vCOtKSCNMD4KqG1ac597ToA7R7yk-qEBe3a426kAp2ykqgKauhSyPOPv3Z3-I4ddkU1Z7n7QdBhptmJLCppsvB_UMmzPUMaQUrXucjqBOBaideixAnQpQiHPSKeLNJWLq99Y8_btcfAbvLoCSpsFFGrVP_7i6BVHB7FZnZ-cDHr2NKmlvR22Nj1ZnZYL_7zJ_AJ7SqPc</recordid><startdate>20040401</startdate><enddate>20040401</enddate><creator>Nikolaeva-Glomb, Lubomira</creator><creator>Galabov, Angel S</creator><general>Elsevier B.V</general><general>Elsevier</general><general>Elsevier Masson</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope><scope>1XC</scope><scope>VOOES</scope></search><sort><creationdate>20040401</creationdate><title>Synergistic drug combinations against the in vitro replication of Coxsackie B1 virus</title><author>Nikolaeva-Glomb, Lubomira ; Galabov, Angel S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c466t-45fa3147dad65fc2abdf836406da7782dc99f16ed8f19f6b8b4a15346d4db04a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral Agents</topic><topic>Antiviral Agents - pharmacology</topic><topic>Benzimidazoles</topic><topic>Benzimidazoles - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Cell Line</topic><topic>Coxsackievirus B1</topic><topic>Drug Combinations</topic><topic>Drug Synergism</topic><topic>Enterovirus</topic><topic>Enterovirus B, Human</topic><topic>Enterovirus B, Human - drug effects</topic><topic>Enterovirus B, Human - growth & development</topic><topic>Humans</topic><topic>Isoxazoles</topic><topic>Isoxazoles - pharmacology</topic><topic>Ketones</topic><topic>Ketones - pharmacology</topic><topic>Life Sciences</topic><topic>Medical sciences</topic><topic>Microbiology and Parasitology</topic><topic>Pharmacology. Drug treatments</topic><topic>Phenylthiourea</topic><topic>Phenylthiourea - analogs & derivatives</topic><topic>Phenylthiourea - pharmacology</topic><topic>Poliovirus</topic><topic>Pyrimidines</topic><topic>Pyrimidines - pharmacology</topic><topic>Synergy</topic><topic>Virus Replication</topic><topic>Virus Replication - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nikolaeva-Glomb, Lubomira</creatorcontrib><creatorcontrib>Galabov, Angel S</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Antiviral research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nikolaeva-Glomb, Lubomira</au><au>Galabov, Angel S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Synergistic drug combinations against the in vitro replication of Coxsackie B1 virus</atitle><jtitle>Antiviral research</jtitle><addtitle>Antiviral Res</addtitle><date>2004-04-01</date><risdate>2004</risdate><volume>62</volume><issue>1</issue><spage>9</spage><epage>19</epage><pages>9-19</pages><issn>0166-3542</issn><eissn>1872-9096</eissn><coden>ARSRDR</coden><abstract>The existence of synergistic drug combinations against the in vitro replication of poliovirus type 1 (Mahoney) (PV-1) had been established in our previous work. The objective of the present study was to test the combined effects of the different drugs against another representative of the
enterovirus genus, i.e. Coxsackievirus B1 (CBV-1). Dual combinations of enviroxime, disoxaril, arildone, PTU-23, HBB and S-7 were evaluated.
The susceptibility of CBV-1 to the individual effects of the inhibitors was compared to that of PV-1. CBV-1 was more sensitive to enviroxime, S-7, PTU-23 and HBB and less sensitive to the effects of disoxaril and arildone. The effect of most dual drug combinations tested against CBV-1 replication was additive or synergistic. Enviroxime and S-7, enviroxime and PTU-23, disoxaril and HBB, disoxaril and PTU-23, arildone and HBB, arildone and PTU-23, S-7 and HBB revealed a strong synergistic effect. Synergy against CBV-1 replication was stronger as compared to that noted for the same drug combinations against PV-1 replication.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>15026197</pmid><doi>10.1016/j.antiviral.2003.11.001</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0166-3542 |
| ispartof | Antiviral research, 2004-04, Vol.62 (1), p.9-19 |
| issn | 0166-3542 1872-9096 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_pasteur_00755462v1 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral Agents Antiviral Agents - pharmacology Benzimidazoles Benzimidazoles - pharmacology Biological and medical sciences Cell Line Coxsackievirus B1 Drug Combinations Drug Synergism Enterovirus Enterovirus B, Human Enterovirus B, Human - drug effects Enterovirus B, Human - growth & development Humans Isoxazoles Isoxazoles - pharmacology Ketones Ketones - pharmacology Life Sciences Medical sciences Microbiology and Parasitology Pharmacology. Drug treatments Phenylthiourea Phenylthiourea - analogs & derivatives Phenylthiourea - pharmacology Poliovirus Pyrimidines Pyrimidines - pharmacology Synergy Virus Replication Virus Replication - drug effects |
| title | Synergistic drug combinations against the in vitro replication of Coxsackie B1 virus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T18%3A36%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Synergistic%20drug%20combinations%20against%20the%20in%20vitro%20replication%20of%20Coxsackie%20B1%20virus&rft.jtitle=Antiviral%20research&rft.au=Nikolaeva-Glomb,%20Lubomira&rft.date=2004-04-01&rft.volume=62&rft.issue=1&rft.spage=9&rft.epage=19&rft.pages=9-19&rft.issn=0166-3542&rft.eissn=1872-9096&rft.coden=ARSRDR&rft_id=info:doi/10.1016/j.antiviral.2003.11.001&rft_dat=%3Cproquest_hal_p%3E17990905%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17990905&rft_id=info:pmid/15026197&rft_els_id=S0166354203002602&rfr_iscdi=true |